Reis Marina, Ribeiro Catarina, Gomes Ana Marta, Santos Clara, Lopes Daniela, Fernandes João Carlos
Nephrology Department, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
Int J Nephrol. 2021 Jan 30;2021:6662488. doi: 10.1155/2021/6662488. eCollection 2021.
Peritonitis is a major peritoneal dialysis complication. Despite a high cure rate, relapsing and repeat peritonitis is associated with Tenckhoff catheter biofilm and multiple episodes of peritoneal damage. In relapsing peritonitis, prompt catheter removal is mandatory; otherwise, in repeat peritonitis, there is not a clear indication for catheter removal. It is questionable if the approach to removal should be different. There are few recent data on repeat and relapsing peritonitis microbiology and clinical outcomes since most studies are from the past decade. This study evaluates the microbiology, clinical outcomes, and impact of relapsing and repeat peritonitis on technique survival and the impact of catheter removal in development of further peritonitis episodes by the same microorganism. We developed a single-center retrospective study from 1998 to 2019 that compared repeat and relapsing peritonitis with a control group in terms of causative microorganisms, cure rate, catheter removal, and permanent and temporary transfer to hemodialysis. We also compared repeat and relapsing peritonitis clinical outcomes when Tenckhoff catheter was not removed. Comparing to the control group, the repeat/relapsing group had a higher cure rate (80.4% 74.5%, =0.01) and lower rate of hospitalization (10.9% versus 27.7%, =0.01). Technique survival was superior in the repeat/relapsing group (log rank = 4.5, =0.03). Gram-positive peritonitis was more common in the repeat/relapsing group especially (43.5% versus 21.3%, =0.01) and Gram-negatives in the control group (26.6% vs 9.0%, =0.02). When the Tenckhoff catheter was not removed after a repeat episode, 58.6% developed a new repeat/relapsing episode versus 60.0% in the relapsing group. Although repeat and relapsing peritonitis have a higher cure rate, it leads to further episodes of peritonitis and consequent morbidity. When Tenckhoff catheter was not removed, the probability of another peritonitis episode by the same microorganism is similar in repeat and relapsing peritonitis.
腹膜炎是腹膜透析的主要并发症。尽管治愈率较高,但复发性和反复性腹膜炎与Tenckhoff导管生物膜及多次腹膜损伤相关。对于复发性腹膜炎,必须及时拔除导管;否则,对于反复性腹膜炎,拔除导管并无明确指征。拔除导管的方法是否应有所不同仍存在疑问。由于大多数研究来自过去十年,近期关于反复性和复发性腹膜炎微生物学及临床结局的数据较少。本研究评估了复发性和反复性腹膜炎的微生物学、临床结局及其对技术生存的影响,以及拔除导管对同一微生物引发进一步腹膜炎发作的影响。我们开展了一项单中心回顾性研究,研究时间为1998年至2019年,比较了反复性和复发性腹膜炎与对照组在致病微生物、治愈率、导管拔除以及永久性和临时性转为血液透析方面的情况。我们还比较了未拔除Tenckhoff导管时反复性和复发性腹膜炎的临床结局。与对照组相比,反复/复发组的治愈率更高(80.4%对74.5%,P = 0.01),住院率更低(10.9%对27.7%,P = 0.01)。反复/复发组的技术生存情况更佳(对数秩检验=4.5,P = 0.03)。革兰阳性菌腹膜炎在反复/复发组更为常见(43.5%对21.3%,P = 0.01),而革兰阴性菌腹膜炎在对照组更为常见(26.6%对9.0%,P = 0.02)。反复性发作后未拔除Tenckhoff导管时,58.6%会出现新的反复/复发发作,而复发性组为60.0%。尽管反复性和复发性腹膜炎的治愈率较高,但会导致进一步的腹膜炎发作及相应的发病率。当未拔除Tenckhoff导管时,反复性和复发性腹膜炎由同一微生物引发另一腹膜炎发作的概率相似。